JP2018534288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534288A5 JP2018534288A5 JP2018519487A JP2018519487A JP2018534288A5 JP 2018534288 A5 JP2018534288 A5 JP 2018534288A5 JP 2018519487 A JP2018519487 A JP 2018519487A JP 2018519487 A JP2018519487 A JP 2018519487A JP 2018534288 A5 JP2018534288 A5 JP 2018534288A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amount
- cytarabine
- aml
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 43
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 42
- 229960000684 cytarabine Drugs 0.000 claims description 42
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 41
- 229940125904 compound 1 Drugs 0.000 claims description 23
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 19
- 229960000975 daunorubicin Drugs 0.000 claims description 19
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 19
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 18
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 18
- 229960000908 idarubicin Drugs 0.000 claims description 18
- 108700028369 Alleles Proteins 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 238000009093 first-line therapy Methods 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 12
- 229960005420 etoposide Drugs 0.000 claims description 12
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 12
- 229960001156 mitoxantrone Drugs 0.000 claims description 12
- 230000000155 isotopic effect Effects 0.000 claims description 10
- 239000002207 metabolite Substances 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 231100000024 genotoxic Toxicity 0.000 claims description 3
- 230000001738 genotoxic effect Effects 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 6
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 6
- 238000000034 method Methods 0.000 description 36
- 239000003112 inhibitor Substances 0.000 description 24
- 239000000126 substance Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BRQZOOWELDMGOE-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C[C]=N1 BRQZOOWELDMGOE-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021087311A JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242256P | 2015-10-15 | 2015-10-15 | |
| US62/242,256 | 2015-10-15 | ||
| US201562255194P | 2015-11-13 | 2015-11-13 | |
| US62/255,194 | 2015-11-13 | ||
| PCT/US2016/057083 WO2017066599A1 (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087311A Division JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534288A JP2018534288A (ja) | 2018-11-22 |
| JP2018534288A5 true JP2018534288A5 (enExample) | 2019-11-28 |
Family
ID=57208385
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519487A Withdrawn JP2018534288A (ja) | 2015-10-15 | 2016-10-14 | 悪性腫瘍の治療のための併用療法 |
| JP2021087311A Pending JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087311A Pending JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10905692B2 (enExample) |
| EP (2) | EP3362057A1 (enExample) |
| JP (2) | JP2018534288A (enExample) |
| KR (2) | KR20250065944A (enExample) |
| CN (1) | CN108366980A (enExample) |
| AU (1) | AU2016340087C1 (enExample) |
| BR (1) | BR112018007304A2 (enExample) |
| CA (1) | CA3001599A1 (enExample) |
| CL (1) | CL2018000927A1 (enExample) |
| EA (1) | EA201890968A1 (enExample) |
| IL (2) | IL311873A (enExample) |
| MX (2) | MX394796B (enExample) |
| SG (1) | SG10201912886XA (enExample) |
| WO (1) | WO2017066599A1 (enExample) |
| ZA (1) | ZA201802088B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| JP7220986B6 (ja) | 2015-02-04 | 2024-02-08 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療効果のある化合物及びその使用方法 |
| CA3002029A1 (en) | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| CA3036053A1 (en) | 2016-09-07 | 2018-03-15 | Celgene Corporation | Tablet compositions |
| US11229653B2 (en) | 2017-05-05 | 2022-01-25 | Celgene Corporation | Methods of treatment of myeloproliferative neoplasm |
| CA3069558A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| US10980788B2 (en) * | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| CN115243690A (zh) | 2019-11-14 | 2022-10-25 | 新基公司 | 用于治疗癌症的儿科制剂 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT998271E (pt) | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ATE340563T1 (de) | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| CA2755394C (en) | 2009-03-13 | 2021-10-19 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| ES2812537T3 (es) * | 2009-10-21 | 2021-03-17 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| AU2013207289B2 (en) | 2012-01-06 | 2017-09-21 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| KR102302091B1 (ko) | 2013-07-11 | 2021-09-16 | 아지오스 파마슈티컬스 아이엔씨. | 암 치료용의 ｉｄｈ２ 돌연변이체 억제제로서의 ｎ,６-비스(아릴 또는 헤테로아릴)-１，３，５-트리아진-２,４-디아민 화합물 |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| MX394658B (es) | 2013-08-02 | 2025-03-24 | Agios Pharmaceuticals Inc | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos |
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| JP7220986B6 (ja) | 2015-02-04 | 2024-02-08 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療効果のある化合物及びその使用方法 |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| CA3002029A1 (en) | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| US20190046512A1 (en) | 2016-02-26 | 2019-02-14 | Agios Pharmaceuticals, Inc. | Idh1 inhibitors for the treatment of haematological malgnancies and solid tumors |
-
2016
- 2016-10-14 CN CN201680060067.1A patent/CN108366980A/zh active Pending
- 2016-10-14 SG SG10201912886XA patent/SG10201912886XA/en unknown
- 2016-10-14 JP JP2018519487A patent/JP2018534288A/ja not_active Withdrawn
- 2016-10-14 WO PCT/US2016/057083 patent/WO2017066599A1/en not_active Ceased
- 2016-10-14 CA CA3001599A patent/CA3001599A1/en not_active Abandoned
- 2016-10-14 AU AU2016340087A patent/AU2016340087C1/en active Active
- 2016-10-14 MX MX2018004595A patent/MX394796B/es unknown
- 2016-10-14 IL IL311873A patent/IL311873A/en unknown
- 2016-10-14 EA EA201890968A patent/EA201890968A1/ru unknown
- 2016-10-14 BR BR112018007304A patent/BR112018007304A2/pt not_active Application Discontinuation
- 2016-10-14 US US15/768,480 patent/US10905692B2/en active Active
- 2016-10-14 KR KR1020257014978A patent/KR20250065944A/ko active Pending
- 2016-10-14 KR KR1020187010260A patent/KR20180063125A/ko not_active Ceased
- 2016-10-14 EP EP16787982.4A patent/EP3362057A1/en not_active Withdrawn
- 2016-10-14 EP EP22196348.1A patent/EP4147692A1/en active Pending
-
2018
- 2018-03-21 IL IL258269A patent/IL258269A/en unknown
- 2018-03-28 ZA ZA2018/02088A patent/ZA201802088B/en unknown
- 2018-04-11 CL CL2018000927A patent/CL2018000927A1/es unknown
- 2018-04-13 MX MX2022006701A patent/MX2022006701A/es unknown
-
2020
- 2020-12-24 US US17/133,994 patent/US20210386749A1/en not_active Abandoned
-
2021
- 2021-05-25 JP JP2021087311A patent/JP2021130682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534288A5 (enExample) | ||
| JP2018535951A5 (enExample) | ||
| JP2018534286A5 (enExample) | ||
| JP2019510746A5 (enExample) | ||
| JP2019513694A5 (enExample) | ||
| JP2020514311A5 (enExample) | ||
| JP2016517851A5 (enExample) | ||
| JP2024133474A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2018536636A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2014513110A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2018517686A5 (enExample) | ||
| FI3362065T3 (fi) | Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi | |
| JP2010515715A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2019517587A5 (enExample) | ||
| IL311873A (en) | Combination therapy for treating malignancies | |
| JP2016513696A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2015512432A5 (enExample) | ||
| JP2019501879A5 (enExample) | ||
| JP2020520957A5 (enExample) |